Combating Emerging and Re-emerging Infectious Diseases in Clinical Trials by Harnessing Innovative Technologies
About This EventThis webinar will highlight the challenges of emerging and re-emerging infectious diseases such as MTB, HIV, MRSA, and Ebola.
This presentation will also provide case studies on how innovative technologies like NGS are utilized to provide a deeper understanding of the pathogen and drug resistance pathways and thus provide better insights into developing diagnostics and therapies that are efficacious against the target pathogen and its resistant variants with improved safety.
Dr. Pany is the Sr. Medical Laboratory Director for the Q2 Solutions Laboratories located at Edinburgh, UK & Centurion, South Africa. He also serves as the Scientific Advisor for Microbiology/Tropical Diseases as part of the Medical and Scientific Affairs teams of Q2 Solutions. His primary responsibility include scientific and technical management of the laboratories and its employees. He also oversees developmental activities for TB and microbiology at Q2 Solutions. Dr. Pany started with Quintiles Clinical Trials Laboratory, Mumbai, in charge of the setting up and operation of bacteriology/molecular biology and mycobacteriology laboratories at Mumbai and Centurion facilities, respectively. Dr. Pany has an MD in microbiology from Bangalore Medical College and Research Institute and an MBBS from MKCG Medical College, Berhampur, Odisha. He holds a life membership of Indian Association of Medical Microbiologists (IAMM) and is also registered as a Professional Natural Scientist with the South African Council for Natural Scientific Professions (SACNASP). He has more than 17 years of experience in the medical field in various capacities – scientist, academician, clinician and surgeon with around 7 years within the clinical trial diagnostic industry. His areas of special interest are infectious diseases clinical trials especially tuberculosis, laboratory management, biosafety, assay development and diagnostics. He has experience as a Research Scientist and coordinator for R&D services at R&D Division (advanced genomics, proteomics and molecular biology), Super Religare Laboratories Ltd., Mumbai, and as Lecturer, Mycobacteriology Section, Department of Microbiology, St. John’s National Academy of Health Sciences, Bangalore. He has presented and published original research and reviews in reputed conferences and journals. Dr. Pany also served as a College of American Pathologists (CAP) Inspector in the fields of microbiology, immunology and molecular biology.
Updated as of September 2018.
Senior Director/General Manager, Central Laboratories South Africa
Sorika van Niekerk is the Sr. Director and General Manager of the Q2 Solutions Laboratory in Pretoria, South Africa. Sorika joined the Clinical Research Industry > 15 years ago in 1999 and her expertise covers all therapeutic areas although there is a specific focus on anti-infective diseases. Whilst being Executive Director Clinical operations at Quintiles she was the main driver behind developing and implementing a strategy to expand Clinical Operations to the rest of Africa. The outcome of this strategy was the opening of office in both East and West Africa. Sorika has a passion for development of people and as such she took responsibility for development of an apprenticeship within the South African contexts. The aim was to increase the availability of well –trained individuals within the clinical trial industry in Sub-Saharan Africa.
Sorika participates as a member on various Industry led initiatives / committees such as the South African Clinical Research Association, Industry Clinical Trial Focus Group comprising of CRO, Pharma and Site representatives, Department of Health Import /export permit committee etc. She also acts as a mentor and promoter of post graduate students specific to the field of research at various Academic institutions.
It was in 2012 that she moved over to the laboratory side of the business as Sr. Director Laboratory Operations, Q2 Solutions, for Sub-Saharan Africa with a special interest and focused strategy to increase the infectious disease footprint for the laboratory and establish the laboratory as a Center of Excellence for Infectious diseases within the global footprint.
Updated as of September 2018.